Mizuho Issues Pessimistic Forecast for MannKind (NASDAQ:MNKD) Stock Price

MannKind (NASDAQ:MNKD) had its target price decreased by research analysts at Mizuho from $8.00 to $7.00 in a report issued on Thursday, MarketBeat Ratings reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s target price indicates a potential upside of 98.86% from the company’s current price.

MNKD has been the subject of a number of other research reports. HC Wainwright raised their price target on shares of MannKind from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research raised shares of MannKind from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Wells Fargo & Company increased their price objective on shares of MannKind from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Thursday. Wall Street Zen cut shares of MannKind from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $3.50 price objective (down from $7.50) on shares of MannKind in a research report on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.84.

MannKind Trading Down 0.8%

MNKD stock opened at $3.52 on Thursday. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -50.28 and a beta of 1.04. MannKind has a 12 month low of $2.23 and a 12 month high of $6.51. The firm has a 50-day moving average of $2.73 and a two-hundred day moving average of $4.59.

MannKind (NASDAQ:MNKD) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The business had revenue of $90.17 million during the quarter, compared to analyst estimates of $105.38 million. MannKind had a negative net margin of 6.63% and a negative return on equity of 11.21%. The firm’s revenue was up 15.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.04 EPS. As a group, equities analysts forecast that MannKind will post -0.02 earnings per share for the current year.

Insider Buying and Selling

In other MannKind news, CEO Michael Castagna purchased 100,000 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $2.59 per share, with a total value of $259,000.00. Following the transaction, the chief executive officer directly owned 2,575,911 shares of the company’s stock, valued at approximately $6,671,609.49. This represents a 4.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On MannKind

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MNKD. AQR Capital Management LLC boosted its position in MannKind by 19.8% in the 1st quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 9,160 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in MannKind by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company’s stock valued at $1,059,000 after buying an additional 6,079 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in MannKind by 8.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company’s stock valued at $3,374,000 after buying an additional 53,202 shares during the period. JPMorgan Chase & Co. boosted its position in MannKind by 42.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,352,017 shares of the biopharmaceutical company’s stock valued at $5,057,000 after buying an additional 404,842 shares during the period. Finally, Prudential Financial Inc. boosted its position in MannKind by 84.8% in the 2nd quarter. Prudential Financial Inc. now owns 37,381 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 17,150 shares during the period. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Key MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: MannKind said it is targeting $110 million to $120 million in 2026 FUROSCIX revenue, which suggests management sees continued commercial growth ahead as key regulatory catalysts approach. Article Title
• Positive Sentiment: RBC raised its price target on MannKind to $4.75 from $3.50, indicating some analysts still see upside despite near-term earnings volatility.
• Neutral Sentiment: TipRanks highlighted that MannKind’s earnings call focused on growth initiatives and navigating earnings volatility, reinforcing that the investment case is now being driven more by future execution than the recent quarter. Article Title
• Neutral Sentiment: MannKind’s Q1 earnings presentation and earnings snapshot provided additional detail on results, but did not change the core takeaway that the quarter was softer than expected. Article Title Article Title
• Negative Sentiment: MannKind reported a Q1 loss of $0.05 per share, wider than the expected $0.02 loss, and revenue of $90.17 million came in below consensus, prompting a negative reaction in the stock. Article Title
• Negative Sentiment: Mizuho cut its price target to $7.00 from $8.00, reflecting some caution ahead of upcoming regulatory and commercial milestones. Article Title

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).